SCHEMBL7659474

SCHEMBL7659474

CN1Cc2cc(NC(=O)CN)ccc2CC(CC(=O)O)C1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 11/20 0.49
ITGA2B P08514 10/20 0.49
ITGAV P06756 3/20 0.49
TERT O14746 1/20 0.40
BRD4 O60885 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.38
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NAMPT P43490 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7539970 0.82 ITGB3 (0.46) ITGB3ITGA2BITGAVNAMPT
SCHEMBL7543230 0.81 ITGB3 (0.46) ITGB3ITGA2BITGAVBRD4POLB
SCHEMBL7333252 0.80 ITGB3 (0.52) ITGB3ITGA2BITGAVHPGD
SCHEMBL7545503 0.80 ITGB3 (0.47) ITGB3ITGA2BITGAVBRD4NAMPT
SCHEMBL7541901 0.80 ITGB3 (0.51) ITGB3ITGA2BITGAVRAB9ANPC1
SCHEMBL7545780 0.80 ITGB3 (0.59) ITGB3ITGA2BITGAVKMT2ARAB9A
SCHEMBL2786534 0.79 ITGB3 (0.52) ITGB3ITGA2BITGAVMEN1KMT2A
SCHEMBL2786598 0.79 ITGB3 (0.52) ITGB3ITGA2BITGAVMEN1KMT2A
SCHEMBL7335166 0.78 ITGB3 (0.49) ITGB3ITGA2BITGAVMEN1KMT2A
SCHEMBL6676170 0.78 ITGB3 (0.56) ITGB3ITGA2BITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458784-B1 PHARMACEUTICALLY ACTIVE BENZODIAZAPINE COMPOUNDS OF FORMULA (I) ARE DISCLOSED. THESE COMPOUNDS INHIBIT THE VITRONECTIN RECEPTOR AND ARE USEFUL FOR TREATMENT OF OSTEOPOROSIS. SMITHKLINE BEECHAM CORPORATION 2002-10-01 US disclosed